{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:33:23Z","timestamp":1740123203258,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"N\u00eemes University Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s11095-021-03137-2","type":"journal-article","created":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T19:02:49Z","timestamp":1638212569000},"page":"1863-1871","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Micafungin Population PK Analysis in Healthy and Septic Pigs: Can the Septic Porcine Model Predict the Micafungin PK in Septic Patients?"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8338-5385","authenticated-orcid":false,"given":"Nicolas","family":"Garbez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Litaty C.","family":"Mbatchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Louart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven C.","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Muller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Lipman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Yves","family":"Lefrant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Roger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,29]]},"reference":[{"key":"3137_CR1","doi-asserted-by":"crossref","unstructured":"Angus DC, van der\u00a0Poll T. Severe Sepsis and Septic Shock. N Engl J Med. 29 ao\u00fbt 2013;369(9):840\u201351.","DOI":"10.1056\/NEJMra1208623"},{"issue":"1","key":"3137_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13613-019-0543-6","volume":"9","author":"A Guillon","year":"2019","unstructured":"Guillon A, Preau S, Aboab J, Azabou E, Jung B, Silva S, et al. Preclinical septic shock research: why we need an animal ICU. Ann Intensive Care d\u00e9c. 2019;9(1):66.","journal-title":"Ann Intensive Care d\u00e9c"},{"issue":"2","key":"3137_CR3","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1177\/0300985811402846","volume":"49","author":"MM Swindle","year":"2012","unstructured":"Swindle MM, Makin A, Herron AJ, Clubb FJ, Frazier KS. Swine as models in biomedical research and toxicology testing. Vet Pathol mars. 2012;49(2):344\u201356.","journal-title":"Vet Pathol mars"},{"issue":"2","key":"3137_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.dci.2014.03.022","volume":"45","author":"KH Mair","year":"2014","unstructured":"Mair KH, Sedlak C, K\u00e4ser T, Pasternak A, Levast B, Gerner W, et al. The porcine innate immune system: an update. Dev Comp Immunol ao\u00fbt. 2014;45(2):321\u201343.","journal-title":"Dev Comp Immunol ao\u00fbt"},{"key":"3137_CR5","first-page":"838","volume":"23","author":"M Balls","year":"1995","unstructured":"Balls M, Goldberg AM, Fentem JH, Broadhead CL, Burch RL, Festing MFW, et al. The Three Rs: The Way Forward. ATLA. 1995;23:838\u201366.","journal-title":"ATLA"},{"issue":"1","key":"3137_CR6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.tim.2011.11.002","volume":"20","author":"F Meurens","year":"2012","unstructured":"Meurens F, Summerfield A, Nauwynck H, Saif L, Gerdts V. The pig: a model for human infectious diseases. Trends Microbiol janv. 2012;20(1):50\u20137.","journal-title":"Trends Microbiol janv"},{"issue":"1","key":"3137_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijantimicag.2011.07.013","volume":"39","author":"M Sinnollareddy","year":"2012","unstructured":"Sinnollareddy M, Peake SL, Roberts MS, Lipman J, Roberts JA. Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review. Int J Antimicrob Agents janv. 2012;39(1):1\u201310.","journal-title":"Int J Antimicrob Agents janv"},{"key":"3137_CR8","doi-asserted-by":"crossref","unstructured":"Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient: Crit Care Med. mars 2009;37(3):840\u201151.","DOI":"10.1097\/CCM.0b013e3181961bff"},{"issue":"2","key":"3137_CR9","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/01.CCM.0000194725.48928.3A","volume":"34","author":"J-L Vincent","year":"2006","unstructured":"Vincent J-L, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, et al. Sepsis in European intensive care units: Results of the SOAP study*. Crit Care Med f\u00e9vr. 2006;34(2):344\u201353.","journal-title":"Crit Care Med f\u00e9vr"},{"key":"3137_CR10","doi-asserted-by":"crossref","unstructured":"Vincent J-L. International Study of the Prevalence and Outcomes of Infection in Intensive Care Units. JAMA. 2 d\u00e9c 2009;302(21):2323.","DOI":"10.1001\/jama.2009.1754"},{"issue":"7","key":"3137_CR11","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1086\/520980","volume":"45","author":"PG Pappas","year":"2007","unstructured":"Pappas PG, Rotstein CMF, Betts RF, Nucci M, Talwar D, Waele JJD, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive Candidiasis. Clin Infect Dis. 2007;45(7):883\u201393.","journal-title":"Clin Infect Dis"},{"key":"3137_CR12","doi-asserted-by":"crossref","unstructured":"Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJC, Baron EJ, et al. Diagnosis and management of complicated intra\u2010abdominal infection in adults and children: guidelines by the surgical infection society and the infectious diseases society of America. Clin Infect Dis. 15 janv 2010;50(2):133\u201164.","DOI":"10.1086\/649554"},{"issue":"3","key":"3137_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s40262-017-0578-5","volume":"57","author":"RE Wasmann","year":"2018","unstructured":"Wasmann RE, Muilwijk EW, Burger DM, Verweij PE, Knibbe CA, Br\u00fcggemann RJ. Clinical pharmacokinetics and pharmacodynamics of micafungin. Clin Pharmacokinet mars. 2018;57(3):267\u201386.","journal-title":"Clin Pharmacokinet mars"},{"issue":"8","key":"3137_CR14","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1007\/s00134-011-2236-y","volume":"37","author":"J Aboab","year":"2011","unstructured":"Aboab J, Sebille V, Jourdain M, Mangalaboyi J, Gharbi M, Mansart A, et al. Effects of esmolol on systemic and pulmonary hemodynamics and on oxygenation in pigs with hypodynamic endotoxin shock. Intensive Care Med ao\u00fbt. 2011;37(8):1344\u201351.","journal-title":"Intensive Care Med ao\u00fbt"},{"key":"3137_CR15","unstructured":"Food and Drug Administration. Guidance for industry: bioanalytical method validation. 2018;Rockville: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM)."},{"issue":"1","key":"3137_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10928-010-9175-z","volume":"38","author":"PLS Chan","year":"2011","unstructured":"Chan PLS, Jacqmin P, Lavielle M, McFadyen L, Weatherley B. The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects. J Pharmacokinet Pharmacodyn f\u00e9vr. 2011;38(1):41\u201361.","journal-title":"J Pharmacokinet Pharmacodyn f\u00e9vr"},{"key":"3137_CR17","doi-asserted-by":"crossref","unstructured":"Garbez N, Mbatchi LC, Maseda E, Luque S, Grau S, Wallis SC, et al. A loading micafungin dose in critically Ill patients undergoing continuous veno-venous hemofiltration or continuous veno-venous hemodiafiltration: a population pharmacokinetic analysis. Ther Drug Monit [Internet]. 30 juill 2021 [cit\u00e9 6 ao\u00fbt 2021]; Disponible sur: https:\/\/journals.lww.com\/drug-monitoring\/Abstract\/9000\/A_Loading_Micafungin_Dose_in_Critically_Ill.98654.aspx","DOI":"10.1097\/FTD.0000000000000874"},{"key":"3137_CR18","doi-asserted-by":"publisher","unstructured":"Garbez N, Mbatchi L, Wallis SC, Muller L, Lipman J, Roberts JA, et al. Prospective cohort study of micafungin population pharmacokinetic analysis in plasma and peritoneal fluid in septic patients with intra-abdominal infections. Antimicrob Agents Chemother [Internet]. 17 juin 2021 [cit\u00e9 6 ao\u00fbt 2021];65(7). Disponible sur: https:\/\/journals.asm.org\/doi\/https:\/\/doi.org\/10.1128\/AAC.02307-20","DOI":"10.1128\/AAC.02307-20"},{"key":"3137_CR19","doi-asserted-by":"crossref","unstructured":"West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science. 4 avr 1997;276(5309):122\u20116.","DOI":"10.1126\/science.276.5309.122"},{"key":"3137_CR20","doi-asserted-by":"crossref","unstructured":"Gumbo T, Hiemenz J, Ma L, Keirns JJ, N. Buell D, Drusano GL. Population pharmacokinetics of micafungin in adult patients. Diagn Microbiol Infect Dis. mars 2008;60(3):329\u201131.","DOI":"10.1016\/j.diagmicrobio.2007.09.018"},{"issue":"10","key":"3137_CR21","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1093\/jac\/dkv173","volume":"70","author":"S Grau","year":"2015","unstructured":"Grau S, Luque S, Campillo N, Sams\u00f3 E, Rodr\u00edguez U, Garc\u00eda-Bernedo CA, et al. Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis. J Antimicrob Chemother. 2015;70(10):2854\u201361.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"3137_CR22","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s40262-017-0509-5","volume":"56","author":"LC Martial","year":"2017","unstructured":"Martial LC, ter Heine R, Schouten JA, Hunfeld NG, van Leeuwen HJ, Verweij PE, et al. Population pharmacokinetic model and pharmacokinetic target attainment of micafungin in intensive care unit patients. Clin Pharmacokinet. 2017;56(10):1197\u2013206.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"3137_CR23","doi-asserted-by":"publisher","first-page":"17741","DOI":"10.1038\/s41598-019-53093-6","volume":"9","author":"S Gastine","year":"2019","unstructured":"Gastine S, Lanckohr C, Blessou M, Horn D, Fobker M, Bause D, et al. Pharmacokinetics of micafungin in critically Ill patients. Sci Rep d\u00e9c. 2019;9(1):17741.","journal-title":"Sci Rep d\u00e9c"},{"issue":"1","key":"3137_CR24","doi-asserted-by":"publisher","first-page":"9233","DOI":"10.1038\/s41598-019-45212-0","volume":"9","author":"W Schelstraete","year":"2019","unstructured":"Schelstraete W, Clerck LD, Govaert E, Millecam J, Devreese M, Deforce D, et al. Characterization of porcine hepatic and intestinal drug metabolizing CYP450: comparison with human orthologues from a quantitative, activity and selectivity perspective. Sci Rep d\u00e9c. 2019;9(1):9233.","journal-title":"Sci Rep d\u00e9c"},{"key":"3137_CR25","doi-asserted-by":"crossref","unstructured":"Hall C, Lueshen E, Mo\u0161at\u2019 A, Linninger AA. Interspecies scaling in pharmacokinetics: a novel whole-body physiologically based modeling framework to discover drug biodistribution mechanisms in vivo. J Pharm Sci. mars 2012;101(3):1221\u201141.","DOI":"10.1002\/jps.22811"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-021-03137-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-021-03137-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-021-03137-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T17:16:30Z","timestamp":1640020590000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-021-03137-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["3137"],"URL":"https:\/\/doi.org\/10.1007\/s11095-021-03137-2","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"type":"print","value":"0724-8741"},{"type":"electronic","value":"1573-904X"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"8 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jeffrey Lipman received honoraria from MSD and Pfizer and received Institution support from MSD. Claire Roger received consultancy fees from MSD, Pfizer, and Fresenius Medical Care.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nicolas Garbez, Litaty Mbatchi, Guillaume Louart, Steven C. Wallis, Laurent Muller, Jason A. Roberts, Jean-Yves Lefrant have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}]}}